{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:20:57Z","timestamp":1793118057467,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007480","name":"University of Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"MICINN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011698","name":"Junta de Comunidades de Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.phrs.2024.107102","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T20:54:59Z","timestamp":1707252899000},"page":"107102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Nanoparticles and siRNA: A new era in therapeutics?"],"prefix":"10.1016","volume":"201","author":[{"given":"Mar\u00eda Dolores","family":"P\u00e9rez-Carri\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Posadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Ce\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6669","key":"10.1016\/j.phrs.2024.107102_bib1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2024.107102_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.phrs.2024.107102_bib3","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.drudis.2021.03.021","article-title":"The era of gene therapy: from preclinical development to clinical application","volume":"26","author":"Alhakamy","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag"},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.phrs.2024.107102_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.phrs.2024.107102_bib7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.phrs.2024.107102_bib8","first-page":"548","article-title":"FDA approves fifth RNAi drug - Alnylam's next-gen hATTR treatment","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol Mol. Biol. Rev."},{"key":"10.1016\/j.phrs.2024.107102_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25010112","article-title":"The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine","volume":"25","author":"Bayda","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.drudis.2020.11.034","article-title":"In vivo therapeutic applications of phosphorus dendrimers: state of the art","volume":"26","author":"Mignani","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"48","key":"10.1016\/j.phrs.2024.107102_bib14","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1039\/C9TB01842E","article-title":"Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers","volume":"7","author":"Raza","year":"2019","journal-title":"J. Mater. Chem. B"},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib15","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.phrs.2024.107102_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2217\/nnm.16.15","article-title":"Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis","volume":"11","author":"Posadas","year":"2016","journal-title":"Nanomed. (Lond. )"},{"issue":"10","key":"10.1016\/j.phrs.2024.107102_bib17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00249-012-0830-8","article-title":"Cationic liposome\/DNA complexes: from structure to interactions with cellular membranes","volume":"41","author":"Caracciolo","year":"2012","journal-title":"Eur. Biophys. J."},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.115.012070","article-title":"Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharm. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/nano9040638","article-title":"Lipid-based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garcia-Pinel","year":"2019","journal-title":"Nanomaterials"},{"issue":"16","key":"10.1016\/j.phrs.2024.107102_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165732","article-title":"Lysosomal storage disease-associated neuropathy: targeting stable nucleic acid lipid particle (SNALP)-formulated siRNAs to the brain as a therapeutic approach","volume":"21","author":"Coutinho","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.phrs.2024.107102_bib21","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","article-title":"Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs","volume":"23","author":"Morrissey","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2024.107102_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1090237","article-title":"The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharm."},{"issue":"32","key":"10.1016\/j.phrs.2024.107102_bib23","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1073\/pnas.0703778104","article-title":"Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes","volume":"104","author":"Rozema","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.phrs.2024.107102_bib24","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.4161\/21645515.2014.982999","article-title":"Regulatory considerations for clinical development of cancer vaccines","volume":"10","author":"Heelan","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"issue":"21","key":"10.1016\/j.phrs.2024.107102_bib25","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: Discovery, pharmacology and clinical development-an introductory review","volume":"180","author":"Ranasinghe","year":"2023","journal-title":"Br. J. Pharm."},{"issue":"12","key":"10.1016\/j.phrs.2024.107102_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"31","key":"10.1016\/j.phrs.2024.107102_bib27","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1073\/pnas.1410741111","article-title":"Comparative proteomic study reveals 17beta-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease","volume":"111","author":"Su","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/a-0784-8827","article-title":"Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments","volume":"57","author":"Roeb","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.phrs.2024.107102_bib29","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14841.1","article-title":"Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts","volume":"7","author":"Weiskirchen","year":"2018","journal-title":"F1000Res"},{"issue":"6","key":"10.1016\/j.phrs.2024.107102_bib30","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1074\/jbc.TM118.002812","article-title":"Roles of the endoplasmic reticulum-resident, collagen-specific molecular chaperone Hsp47 in vertebrate cells and human disease","volume":"294","author":"Ito","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2024.107102_bib31","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1172\/JCI117617","article-title":"Coexpression of the collagen-binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) collagen genes in carbon tetrachloride-induced rat liver fibrosis","volume":"94","author":"Masuda","year":"1994","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib32","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.32181","article-title":"BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","volume":"75","author":"Lawitz","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2024.107102_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12703\/b\/9-1","article-title":"Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management","volume":"9","author":"Santos","year":"2020","journal-title":"Fac. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib34","first-page":"172","article-title":"Alpha-1 antitrypsin deficiency-mediated liver toxicity: why do some patients do poorly? What do we know so far?","volume":"7","author":"Bouchecareilh","year":"2020","journal-title":"Chronic Obstr. Pulm. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jhep.2021.11.022","article-title":"Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder","volume":"76","author":"Fromme","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2024.107102_bib36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coph.2021.06.001","article-title":"Alpha1-antitrypsin deficiency: new therapies on the horizon","volume":"59","author":"Remih","year":"2021","journal-title":"Curr. Opin. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2024.107102_bib37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for liver disease associated with alpha(1)-antitrypsin deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.phrs.2024.107102_bib38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.phrs.2024.107102_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-023-01160-9","article-title":"Stratification in heterozygous familial hypercholesterolemia: imaging, biomarkers, and genetic testing","author":"Corral","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107102_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum. Mutat."},{"issue":"20","key":"10.1016\/j.phrs.2024.107102_bib42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"9911","key":"10.1016\/j.phrs.2024.107102_bib43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.phrs.2024.107102_bib44","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib46","first-page":"76","article-title":"Lipoprotein (a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranhao","year":"2014","journal-title":"Arq. Bras. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2024.107102_bib47","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res"},{"issue":"11","key":"10.1016\/j.phrs.2024.107102_bib48","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/ATVBAHA.122.318177","article-title":"Regulated necrosis in atherosclerosis","volume":"42","author":"Puylaert","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2024.107102_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2022.03.029","article-title":"Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease","volume":"349","author":"Rider","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2024.107102_bib50","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The Roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Boren","year":"2020","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"5908","key":"10.1016\/j.phrs.2024.107102_bib51","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.phrs.2024.107102_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107102_bib53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and Pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MOL.0000000000000747","article-title":"Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management","volume":"32","author":"Ying","year":"2021","journal-title":"Curr. Opin. Lipido"},{"issue":"9","key":"10.1016\/j.phrs.2024.107102_bib56","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1515\/bmc-2013-0038","article-title":"Transthyretin: a multifaceted protein","volume":"5","author":"Vieira","year":"2014","journal-title":"Biomol. Concepts"},{"issue":"2","key":"10.1016\/j.phrs.2024.107102_bib58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2024.107102_bib59","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11912-023-01397-2","article-title":"Emerging therapies for transthyretin amyloidosis","volume":"25","author":"Tsoi","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.phrs.2024.107102_bib60","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.phrs.2024.107102_bib61","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"issue":"10040","key":"10.1016\/j.phrs.2024.107102_bib63","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2024.107102_bib64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjh.13365","article-title":"The current status of prophylactic replacement therapy in children and adults with haemophilia","volume":"169","author":"Ljung","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107102_bib65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3324\/haematol.2014.112821","article-title":"Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity","volume":"100","author":"Oldenburg","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.phrs.2024.107102_bib66","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107102_bib67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/IJNRD.S129227","article-title":"Primary IgA nephropathy: current challenges and future prospects","volume":"11","author":"Penfold","year":"2018","journal-title":"Int J. Nephrol. Renov. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2024.107102_bib68","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Fontan","year":"2023","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.phrs.2024.107102_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1216094","article-title":"Advances in the study of B cells in renal ischemia-reperfusion injury","volume":"14","author":"Fan","year":"2023","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107102_bib70","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1681\/ASN.2008111204","article-title":"siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury","volume":"20","author":"Molitoris","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"14","key":"10.1016\/j.phrs.2024.107102_bib71","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.120.053029","article-title":"Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study","volume":"144","author":"Thielmann","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2024.107102_bib72","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jhep.2018.03.012","article-title":"Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients","volume":"69","author":"Turner","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2024.107102_bib73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O'Donoghue","year":"2022","journal-title":"Am. Heart J."},{"issue":"10386","key":"10.1016\/j.phrs.2024.107102_bib74","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.phrs.2024.107102_bib75","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6030063","article-title":"Inclisiran: a new promising agent in the management of hypercholesterolemia","volume":"6","author":"Kosmas","year":"2018","journal-title":"Diseases"},{"issue":"18","key":"10.1016\/j.phrs.2024.107102_bib77","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.phrs.2024.107102_bib78","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.phrs.2024.107102_bib79","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/FJC.0000000000001053","article-title":"Inclisiran: a novel agent for lowering apolipoprotein B-containing lipoproteins","volume":"78","author":"Warden","year":"2021","journal-title":"J. Cardiovasc Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.phrs.2024.107102_bib81","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1210\/clinem\/dgab876","article-title":"New therapies for primary hyperlipidemia","volume":"107","author":"Aguilar-Salinas","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14218\/JCTH.2014.00039","article-title":"Acute hepatic porphyria","volume":"3","author":"Bissell","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.phrs.2024.107102_bib86","first-page":"17.20.1","article-title":"Porphyria diagnostics-part 1: a brief overview of the porphyrias","volume":"86","author":"Ramanujam","year":"2015","journal-title":"Curr. Protoc. Hum. Genet"},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib87","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MOG.0000000000000734","article-title":"Novel treatment options for acute hepatic porphyrias","volume":"37","author":"Wang","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107102_bib88","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"24","key":"10.1016\/j.phrs.2024.107102_bib89","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107102_bib90","series-title":"Primary Hyperoxaluria Type 1","author":"Milliner","year":"1993"},{"key":"10.1016\/j.phrs.2024.107102_bib91","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/864580","article-title":"Primary hyperoxaluria","volume":"2011","author":"Harambat","year":"2011","journal-title":"Int J. Nephrol."},{"issue":"7","key":"10.1016\/j.phrs.2024.107102_bib92","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.phrs.2024.107102_bib93","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"13","key":"10.1016\/j.phrs.2024.107102_bib94","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.phrs.2024.107102_bib95","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.phrs.2024.107102_bib96","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pedia Nephrol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107102_bib97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107102_bib99","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","author":"Raal","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2024.107102_bib100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/HCO.0000000000000657","article-title":"Future role of proprotein convertase subtilisin\/kexin type 9 inhibitors in preventive cardiology","volume":"34","author":"Mahmood","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107102_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.phrs.2024.107102_bib103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.phrs.2024.107102_bib104","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40262-023-01292-w","article-title":"Pharmacokinetics and pharmacodynamics of patisiran in patients with hATTR amyloidosis and with polyneuropathy after liver transplantation","volume":"62","author":"Badri","year":"2023","journal-title":"Clin. Pharm."},{"issue":"17","key":"10.1016\/j.phrs.2024.107102_bib105","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"34","key":"10.1016\/j.phrs.2024.107102_bib106","doi-asserted-by":"crossref","first-page":"18760","DOI":"10.1021\/jacs.3c07337","article-title":"Targeted and equally distributed delivery of mRNA to organs with pentaerythritol-based one-component ionizable amphiphilic janus dendrimers","volume":"145","author":"Lu","year":"2023","journal-title":"J. Am. Chem. Soc."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182400046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182400046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:51:27Z","timestamp":1760914287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182400046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":106,"alternative-id":["S104366182400046X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107102","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles and siRNA: A new era in therapeutics?","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107102"}}